| Theme | Treatment of Acid‒related Diseases -- the Past, Present and Future | |
|---|---|---|
| Title | Potassium—competitive Acid Blocker (P—CAB) | |
| Publish Date | 2017/02 | |
| Author | Yoshikazu Kinoshita | Department of Gastroenterology and Hepatology, Shimane University School of Medicine |
| Author | Hironobu Mikami | Department of Gastroenterology and Hepatology, Shimane University School of Medicine |
| Author | Eiko Okimoto | Department of Gastroenterology and Hepatology, Shimane University School of Medicine |
| Author | Mayumi Okada | Department of Gastroenterology and Hepatology, Shimane University School of Medicine |
| [ Summary ] | The clinical application of a newly developed gastric acid‒suppressing drug, vonoprazan, has begun. Vonoprazan is a potassium‒competitive acid blocker (P‒CAB) and has a faster and more potent acid‒suppressing effect than proton‒pump inhibitors (PPI). It also elevates nocturnal intra‒gastric pH with its once‒daily morning dose, because of its long plasma half‒life. Vonoprazan is an effective and safe therapeutic drug for acid related diseases when it is used for short‒term treatment. However, for long‒term treatment with vonoprazan, possible acid suppression‒related adverse events like those recently recognized in long‒term PPI therapy, still need to be considered. Further studies concerning the safety of long‒term vonoprazan therapy needs to be accelerated. | |